Aptevo Therapeutics (APVO) Change in Accured Expenses (2016 - 2023)
Historic Change in Accured Expenses for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to -$76000.0.
- Aptevo Therapeutics' Change in Accured Expenses fell 10881.67% to -$76000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $1.1 million, marking a year-over-year increase of 16974.42%. This contributed to the annual value of $518000.0 for FY2023, which is 23147.21% up from last year.
- As of Q3 2023, Aptevo Therapeutics' Change in Accured Expenses stood at -$76000.0, which was down 10881.67% from $1.1 million recorded in Q2 2023.
- Aptevo Therapeutics' 5-year Change in Accured Expenses high stood at $2.1 million for Q4 2020, and its period low was -$3.2 million during Q1 2020.
- Over the past 5 years, Aptevo Therapeutics' median Change in Accured Expenses value was -$42000.0 (recorded in 2021), while the average stood at -$293631.6.
- Examining YoY changes over the last 5 years, Aptevo Therapeutics' Change in Accured Expenses showed a top increase of 54954.55% in 2022 and a maximum decrease of 334523.81% in 2022.
- Aptevo Therapeutics' Change in Accured Expenses (Quarter) stood at -$2.5 million in 2019, then skyrocketed by 183.71% to $2.1 million in 2020, then plummeted by 110.37% to -$220000.0 in 2021, then skyrocketed by 549.55% to $989000.0 in 2022, then tumbled by 107.68% to -$76000.0 in 2023.
- Its Change in Accured Expenses was -$76000.0 in Q3 2023, compared to $1.1 million in Q2 2023 and -$909000.0 in Q1 2023.